# Trakya University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/trakya-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 40 |
| Citations | 345,909 |
| City | Edirne |
| Country | TR |
| Description | Trakya University is a research organisation in Edirne, TR. OpenAlex records 15,424 works and 345,909 citations for it. 4,067 researchers list it as their most recent affiliation. |
| Homepage | https://www.trakya.edu.tr |
| OpenAlex ID | https://openalex.org/I12387023 |
| Researchers | 4,067 |
| ROR ID | https://ror.org/00xa0xn82 |
| Type | education |
| Wikidata ID | https://www.wikidata.org/wiki/Q845682 |
| Works | 15,424 |

## University papers

- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407](https://scholariq.org/papers/a-randomized-placebo-controlled-trial-of-pembrolizumab-plus-chemotherapy-in/)
- [Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer](https://scholariq.org/papers/effect-of-first-line-serplulimab-vs-placebo-added-to-chemotherapy-on-survival-in/)
- [Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study](https://scholariq.org/papers/pembrolizumab-plus-ipilimumab-or-placebo-for-metastatic-non-small-cell-lung/)
- [Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer](https://scholariq.org/papers/ensartinib-vs-crizotinib-for-patients-with-anaplastic-lymphoma-kinase-positive/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-in-patients-with/)
- [Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial](https://scholariq.org/papers/telisotuzumab-vedotin-monotherapy-in-patients-with-previously-treated-c-met/)

## University top topics

Showing 8 of 14.

- [Education Practices and Challenges](https://scholariq.org/topics/education-practices-and-challenges/)
- [Insect-Plant Interactions and Control](https://scholariq.org/topics/insect-plant-interactions-and-control/)
- [Impact of Technology on Adolescents](https://scholariq.org/topics/impact-of-technology-on-adolescents/)
- [Cardiac Imaging and Diagnostics](https://scholariq.org/topics/cardiac-imaging-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Water Quality and Pollution Assessment](https://scholariq.org/topics/water-quality-and-pollution-assessment/)
- [Anesthesia and Pain Management](https://scholariq.org/topics/anesthesia-and-pain-management/)
- [Inflammatory Biomarkers in Disease Prognosis](https://scholariq.org/topics/inflammatory-biomarkers-in-disease-prognosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.